The release of Semaglutide at a 45mg level represents a important advance in addressing type 2 diabetes. Previously, lower doses were typically administered, but this latest formulation offers the potential for greater glucose control in some people. Clinicians are evaluating its effectiveness and security profile, particularly in those who didn’